For the quarter ending 2026-03-31, CRVS had $35,526K increase in cash & cash equivalents over the period. -$10,465K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Change in fair value of warrant liability | - | 0 | 0 | -27,141 |
| Net loss | -13,692 | -12,321 | -10,157 | 7,195 |
| Depreciation and amortization | 29 | 26 | 28 | 51 |
| Accretion related to marketable securities | 17 | 261 | 459 | 625 |
| Stock-based compensation | 2,650 | 1,574 | 1,249 | 2,507 |
| Loss from equity method investment | -599 | -707 | -323 | -928 |
| Accounts receivable - related party | - | - | -54 | 11 |
| Accounts receivable | 6 | -38 | - | - |
| Prepaid and other current assets | 1,762 | 204 | -64 | -1,081 |
| Operating lease right-of-use asset | -88 | -88 | -85 | -165 |
| Other assets | 865 | 3 | 226 | -6 |
| Accounts payable | 2,206 | 517 | -1,163 | 555 |
| Accrued and other liabilities | 499 | 765 | 708 | 1,288 |
| Operating lease liability | -103 | -74 | -72 | -39 |
| Net cash used in operating activities | -10,374 | -9,191 | -9,566 | -14,040 |
| Purchases of marketable securities | 161,737 | 13,418 | 31,149 | 47,183 |
| Maturities of marketable securities | 16,982 | 24,323 | 28,531 | 31,274 |
| Purchases of property and equipment | 91 | 25 | 0 | 149 |
| Net cash (used in) provided by investing activities | -144,846 | 10,880 | -2,618 | -16,058 |
| Proceeds from the exercise of common stock warrants (includes 4,960 in aggregate gross proceeds from related parties for the year ended december 31, 2025) | - | 0 | 0 | 35,745 |
| Proceeds from issuance of common stock in connection with follow-on public offering, net | 189,407 | - | - | - |
| Proceeds from exercise of common stock options | 1,339 | 20 | 360 | 304 |
| Net cash provided by financing activities | 190,746 | 20 | 360 | 36,049 |
| Net increase (decrease) in cash and cash equivalents | 35,526 | 1,709 | -11,824 | 5,951 |
| Cash and cash equivalents at beginning of the period | 4,576 | 2,867 | 8,740 | - |
| Cash and cash equivalents at end of the period | 40,102 | 4,576 | 2,867 | - |
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)